Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On September 15, 2025, Can-Fite BioPharma announced a significant clinical finding in its compassionate use program for decompensated liver cirrhosis. A patient treated with Namodenoson showed a complete resolution of esophageal varices, a severe complication of advanced liver disease. This outcome, confirmed by endoscopic evaluation, suggests a potential disease-modifying effect of Namodenoson. The drug is currently in Phase III trials for hepatocellular carcinoma and has shown promise in treating other conditions, highlighting its therapeutic potential in a market with limited treatment options.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score reflects significant financial challenges and bearish technical indicators. The company’s persistent financial losses and reliance on external financing are major concerns, compounded by negative technical signals. The absence of profitability metrics further underscores the risks associated with this stock.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is in an advanced clinical stage with a platform technology aimed at multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory diseases. Its lead drug candidates include Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma, among others.
Average Trading Volume: 204,773
Technical Sentiment Signal: Sell
Current Market Cap: $14.18M
Learn more about CANF stock on TipRanks’ Stock Analysis page.